PubRank

Peter Carroll

Author PubWeight™ 36.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prostate specific antigen best practice statement: 2009 update. J Urol 2009 3.95
2 Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003 2.34
3 Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005 2.29
4 Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008 2.23
5 Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2010 1.89
6 Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005 1.85
7 Mouse urogenital development: a practical approach. Differentiation 2003 1.59
8 High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol 2003 1.57
9 A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res 2009 1.56
10 Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clin Cancer Res 2012 1.39
11 Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int 2014 1.08
12 Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006 1.04
13 Prostate specific antigen best practice statement: 2009 update. J Urol 2013 1.03
14 Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging 2014 1.02
15 Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 2006 1.01
16 CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 2005 1.00
17 A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009 0.92
18 Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol 2012 0.91
19 Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun 2003 0.88
20 Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 2005 0.88
21 CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 2002 0.84
22 CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 2005 0.84
23 Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology 2008 0.83
24 Molecular analysis of WFDC1/ps20 gene in prostate cancer. Prostate 2004 0.82
25 Doctors, patients and the Internet: time to grasp the nettle. Clin Med 2002 0.82
26 The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. J Clin Nurs 2011 0.80
27 Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013 0.80
28 Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology 2007 0.78
29 Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. BJU Int 2009 0.77
30 Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. J Urol 2005 0.75
31 Salvage therapies after radiation therapy. Urol Oncol 2012 0.75
32 Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol 2016 0.75